Mobile

A Phase 2a, Open-label, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intranasal Clonazepam in Adult Subjects with Epileptic Seizures

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-003307-13

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To determine the minimum effective dose (MED) of intranasal clonazepam, defined as the lowest dose that can effectively reduce epileptiform activity in adult epilepsy subjects over the 24 hours following the onset of an epileptic seizure.

Critère d'inclusion

  • Recurrent Acute Repetitive Seizures (ARS)

Liens